NCT02554942View on ClinicalTrials.gov

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions

Anemia

Interventions

DRUG

Epoetin beta

Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.

Trial Locations (13)

10003

Cáceres

30120

El Palmar Murcia

37007

Salamanca

38320

San Cristóbal de La Laguna

46010

Valencia

46026

Valencia

48903

Barakaldo

50009

Zaragoza

03804

Alcoy

08036

Barcelona

08041

Barcelona

08916

Barcelona

08243

Manresa

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02554942 - A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter